CSIMarket
 
Rain Oncology Inc   (RAIN)
Other Ticker:  
 
 
Price: $1.2100 $-0.02 -1.626%
Day's High: $1.27 Week Perf: -1.63 %
Day's Low: $ 1.21 30 Day Perf: 0.00
Volume (M): 3,706 52 Wk High: $ 1.27
Volume (M$): $ 4,484 52 Wk Avg: $1.16
Open: $1.24 52 Wk Low: $0.99



 Market Capitalization (Millions $) 44
 Shares Outstanding (Millions) 36
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -72
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 1

Rain Oncology Inc
Rain Therapeutics Inc. is a clinical-stage biotechnology company that was founded in 2017 and is headquartered in Newark, California. The company is focused on developing targeted therapies for cancer patients. Rain Therapeutics aims to provide effective therapies to patients who have limited treatment options.

The company's lead drug candidate is called RAIN-32, which targets a specific genetic mutation that is present in a variety of tumors, including non-Hodgkin's lymphoma, solid tumors, and certain types of leukemia. RAIN-32 is currently in clinical testing, and the preliminary results have been promising. Rain Therapeutics also has several other drug candidates in preclinical development.

Rain Therapeutics is led by a team of experienced executives with a track record of success in the biotechnology industry. The company's CEO is Avanish Vellanki, who has over 20 years of experience in the biotech industry.

In addition to its focus on developing targeted therapies, Rain Therapeutics is committed to addressing the unmet needs of cancer patients. The company is actively engaged in working with advocacy groups to raise awareness about the disease and the need for new treatments.

Rain Therapeutics has raised over $120 million in funding to date from investors, including RTW Investments, BVF Partners, and Perceptive Advisors. The company is well-positioned to advance its drug candidates through clinical development and bring new therapies to patients who need them.


   Company Address: 8000 Jarvis Avenue Newark 94560 CA
   Company Phone Number: 953-5559   Stock Exchange / Ticker: NASDAQ RAIN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE   -10.62%    
BPMC        9.74% 
KURA   -0.73%    
MRTX   -0.47%    
ZYME        12.67% 
IOVA   -7.47%    
• View Complete Report
   



Stock Market Announcement

Rain Oncology's Merger with Pathos AI: Pioneering the Future of Oncology with AI-Powered Solutions

Published Wed, Dec 13 2023 11:06 PM UTC


In a significant development within the biotechnology industry, Rain Oncology Inc. (NASDAQ: RAIN) has announced its entry into a definitive merger agreement with Pathos AI Inc. (Pathos), a pioneering artificial intelligence (AI) company. As per the agreement, Pathos will acquire Rain at an impressive offer of $1.16 in cash per share, complemented by a non-tradeable cont...

Rain Oncology Inc

Rain Oncology Inc's Third Quarter of 2023 Sees Dark Clouds as Operating Losses Dampen Growth

The Major Pharmaceutical Preparations sector has been closely observing the third quarter results of 2023, particularly focusing on Rain Oncology Inc. The company reported an operating loss of $-8.078 million during this period, with no mention of any revenue. As a result, their performance in this quarter has overshadowed their performance in the same period last year.
Rain Oncology Inc primarily operates in the development cycle, and this has been a key takeaway from the latest news. Despite the operating loss, there has been some satisfaction with the deficit as it has been significantly trimmed compared to the same timeframe in 2022. In the third quarter of 2022, the deficit stood at $-18.041 million, while in the third quarter of 2023, it reduced to $-7.034 million. This improvement is a positive sign for the company.

Rain Oncology Inc

Rain Oncology Inc Faces Financial Setback: Operating Deficit Grows to $23 Million in Q2 2023

Rain Oncology Inc, a major player in the pharmaceutical preparations industry, is under scrutiny as industry insiders dissect the second quarter results of 2023. The company's financial performance has raised concerns among market participants, especially due to its operating deficit of $-23.231 million during the April to June 30 2023 reporting period. What adds to the worry is the fact that Rain Oncology Inc has not generated any revenue during this time.
Comparing the figures to the same quarter in 2022, the operating deficit has increased from $-17.718 million, indicating a further decline in the company's financial health. Additionally, Rain Oncology Inc recorded a net loss of $-22.064 million for the second quarter of 2023, which is a significant widening from the net loss of $-17.611 million in the previous year.

Rain Oncology Inc

Rain Oncology Inc Faces Operating Deficit in Q1 2023: Strategies to Overcome Challenges and Fuel Future Growth

The Major Pharmaceutical Preparations industry has faced some challenges in the first quarter of 2023, with an operating deficit of $-21.743 million, and no mention of revenue for the period between January and March 31. This has led to market participants speculating when the company will begin to report revenue, and how this will affect its financial performance moving forward.
However, despite these initial setbacks, there are still reasons to be bullish about the future of the Major Pharmaceutical Preparations industry and companies like Rain Oncology Inc. For one, the industry has shown remarkable resilience in the face of global challenges, including the ongoing COVID-19 pandemic. Pharmaceutical companies have been at the forefront of developing and distributing vaccines, treatments, and other innovative solutions to combat the virus, and this has helped to boost their reputation and attract more investment.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com